TwinStrand Biosciences is a biotechnology company specializing in the development of highly sensitive and accurate assays for the detection of mutations in DNA. Their proprietary Duplex Sequencing technology enables the detection of rare mutations with unprecedented accuracy, which is crucial for applications in cancer research, liquid biopsy, and monitoring of minimal residual disease.

TwinStrand Biosciences

TwinStrand Biosciences Duplex Sequencing patent estate is the foundational technology enabling the ability to accurately identify ultra-low frequency genomic variants that are undetectable by conventional NGS methods. The company's highly sensitive and specific patented Duplex Sequencing technology delivers clearer insights to researchers in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in public health, and other fields of science on a faster timescale when actions are most impactful. TwinStrand's scientist-leaders have authored more than thirty peer-reviewed articles using Duplex Sequencing technology and have developed a portfolio of more than 150 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks, molecular diagnostic companies and federal regulatory agencies to bring high precision genomics to the forefront of their science.

COM:TWINSTRANDBIO

TwinStrand Biosciences

Financials Not Available